Nonalcoholic fatty liver disease and cardiovascular disease risk.
Nonalcoholic fatty liver disease (NAFLD) is prevalent in people with the metabolic syndrome and type 2 diabetes. Evidence is now accumulating that NAFLD is associated with obesity and diabetes and may serve as a predictor of cardiovascular disease. Although at present, treatment of the individual risk factors pertinent to NAFLD is advocated, novel therapies are emerging that may target steatosis and/or inflammation, thus ameliorating the overall cardiovascular disease risk. Long-term outcome studies need to establish whether treatment of NAFLD (and in particular which therapy) will affect the long-term outcome.
Schindhelm
Roger K
RK
Department of Endocrinology/Diabetes Center,VU University Medical Center, PO Box 7057,1007 MB Amsterdam, The Netherlands.
Diamant
Michaela
M
Heine
Robert J
RJ
D002318:Cardiovascular Diseases / Q000150:complications* / Q000201:enzymology / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000201:enzymology / Q000453:epidemiology; D005234:Fatty Liver / Q000150:complications* / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000150:complications / Q000453:epidemiology